GLP-1 Side Effects: What's Common, Serious & How to Manage | PlexusDx

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Most GLP-1 side effects are gastrointestinal, predictable, and time-limited. The FDA labels for Wegovy, Ozempic, Rybelsus, Zepbound, and Mounjaro describe a consistent pattern: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue dominate the first 4–8 weeks; serious events like pancreatitis and gallbladder disease are rare; and the boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies. This article walks through what to expect, what to escalate, and how PlexusDx structures titration and the optional Precision Peptide Genetic Test so dose decisions are anchored to your biology — not a population average. PlexusDx prescribes compounded semaglutide and tirzepatide, which are not FDA-approved finished drugs; the active-ingredient safety profile mirrors the labeled GLP-1 class, and every protocol is supervised by a licensed clinician. Discuss any medication change with your provider.

Common GLP-1 side effects: what the FDA labels actually say

The labeled adverse-reaction tables for Wegovy (semaglutide 2.4 mg weekly) and Zepbound (tirzepatide) consistently rank gastrointestinal symptoms at the top. Nausea is the most common, followed by diarrhea, vomiting, constipation, and abdominal pain. Headache, fatigue, GERD, eructation (burping), and mild hair loss appear at lower rates. Injection-site reactions are documented for the weekly injectables. These rates come from specific FDA trials at specific doses, so cross-product comparisons are imperfect, but the pattern holds across the GLP-1 class: most users feel something, most of those somethings are GI, and most resolve as the body adapts. PlexusDx Semaglutide Injection ($149/mo) and Tirzepatide Injection ($249/mo) use the same active ingredients as the branded products, so patients should expect a similar GI-dominant side-effect profile and a similar timeline.

Serious but rare GLP-1 side effects you should recognize

Less common but clinically important reactions documented in FDA labeling include pancreatitis (severe, persistent abdominal pain that may radiate to the back, often with vomiting), gallbladder disease (right upper quadrant pain, sometimes with fever or jaundice), acute kidney injury (often related to severe dehydration from vomiting and diarrhea), severe hypersensitivity reactions, and diabetic retinopathy complications in patients with pre-existing retinopathy on semaglutide. Hypoglycemia is uncommon as monotherapy in non-diabetic users but rises when GLP-1s are combined with insulin or sulfonylureas. Pulmonary aspiration during anesthesia has been reported and is the basis of perioperative guidance. None of these are common, but each warrants prompt clinical attention. Stop the medication and contact your provider or seek emergency care for severe abdominal pain, persistent vomiting, signs of severe dehydration, sudden vision changes, or symptoms of an allergic reaction.

The boxed warning: thyroid C-cell tumors with semaglutide AND tirzepatide

Both semaglutide-containing products (Wegovy, Ozempic, Rybelsus) and tirzepatide-containing products (Zepbound, Mounjaro) carry an FDA boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies; a causal relationship in humans has not been established, but the warning applies to the entire class of long-acting GLP-1 receptor agonists used for weight management and type 2 diabetes. The label contraindication is firm: do not use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This contraindication applies equally to compounded semaglutide and tirzepatide because the active ingredient is the same. Patients with these histories should not start any GLP-1 protocol — PlexusDx, branded, or otherwise — and any unexplained neck mass, hoarseness, persistent dysphagia, or shortness of breath while on therapy should prompt immediate clinical evaluation. PlexusDx clinicians screen for these contraindications at intake.

When to call your provider: a simple decision frame

Use a three-tier framework. Manage at home: mild to moderate nausea, occasional vomiting that resolves, soft stools or mild diarrhea for a few days, mild constipation, mild headache, mild fatigue in the first 4–8 weeks — these are typical and usually improve with hydration, smaller meals, and time. Contact your provider within 24–48 hours: nausea or vomiting that prevents you from keeping fluids down for half a day, diarrhea that lasts more than a few days, constipation that doesn't respond to fiber and water, persistent fatigue beyond the early titration window, injection-site reactions that worsen rather than improve. Seek immediate care: severe persistent abdominal pain (especially radiating to the back), inability to keep any fluids down for 24 hours, vomiting blood, signs of severe dehydration (dizziness, very dark urine, confusion), sudden vision changes, swelling of the face or throat, difficulty breathing, or symptoms of a severe allergic reaction. PlexusDx patients have async messaging access to the clinical team between visits for the yellow-tier questions.

Managing side effects with slow titration

The most reliable side-effect mitigation strategy across the GLP-1 class is unhurried dose escalation. FDA labels for Wegovy and Zepbound both prescribe stepwise titration over multiple months specifically because slower up-titration reduces nausea, vomiting, and discontinuation. Practical steps that match clinical guidance: eat smaller, more frequent meals; reduce high-fat, fried, very spicy, and very sweet foods during dose increases; avoid carbonated drinks and large boluses of liquid right before or during meals; prioritize protein and fiber; hydrate steadily through the day; limit alcohol, which can worsen nausea, dehydration, and hypoglycemia risk. PlexusDx structures all six protocols with provider-guided titration and offers four mechanism classes — Microdose GLP-1 Protocol ($129/mo flat) for the lowest-exposure starting point, Semaglutide Injection for the standard weekly path, Tirzepatide Injection for the dual-agonist option that some patients tolerate differently than semaglutide, and GLP-Squared for provider-titrated combination escalation later in the protocol when appropriate. If side effects persist past the typical 4–8 week adaptation window, dose adjustment, slower titration, or switching mechanisms are documented options to discuss with your prescriber.

The genetic angle: why two patients on the same dose feel different

Side-effect tolerance and weight-loss response on GLP-1 therapy vary substantially between individuals, and a portion of that variability is genetic. Variants in genes including GIPR (the receptor tirzepatide engages alongside GLP-1), GLP1R, FTO, MC4R, and TCF7L2 have been associated in published research with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test sequences 48 unique genes and 57 genetic variants across 14 health pathways, returning 150+ insights including 34 weight-management-specific findings — the GIPR rs1800437 variant is the headline marker for differential GLP-1 response. The test informs the clinical conversation at the start of treatment so titration speed and mechanism choice (semaglutide-first vs tirzepatide-first vs microdose vs combination) are anchored to a measurable baseline rather than starting from a population-average schedule. The test is $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol. Genetic testing does not replace the FDA-labeled contraindications, the boxed warning, or clinical judgment — it adds a data point to a decision your prescriber still makes.

Frequently asked questions

Do GLP-1 side effects go away over time?

For most people, yes. The labeled GI side effects — nausea, vomiting, diarrhea, constipation — are most intense during the first 4–8 weeks and around each dose increase, then improve as the body adapts. If symptoms persist beyond 2–3 months or remain intolerable, talk to your prescriber about slowing titration, lowering the dose, or switching mechanisms; PlexusDx clinicians have all three levers available.

Which GLP-1 has the fewest side effects?

It varies by individual and by symptom. Trial data suggest tirzepatide tends to show somewhat lower nausea and vomiting rates than semaglutide at comparable weight-loss endpoints, though both share the same GI-dominant profile. Liraglutide (daily injection) historically shows higher discontinuation. PlexusDx offers both semaglutide and tirzepatide so patients can switch under clinical supervision if one mechanism is poorly tolerated.

Does the thyroid boxed warning apply to compounded semaglutide and tirzepatide?

Yes — the boxed warning is tied to the active ingredient, not the brand. Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use semaglutide or tirzepatide in any form, branded or compounded. PlexusDx screens for this contraindication at intake and will not prescribe these protocols to patients with that history.

Should I stop my GLP-1 before surgery?

Discuss it with your surgical and prescribing teams. FDA labeling notes that pulmonary aspiration has been reported during anesthesia in patients on GLP-1 therapy, and multi-society perioperative guidance has been issued. Do not stop on your own; the decision depends on the procedure, the GLP-1 product, your dose, and your last dose timing.

Can the Precision Peptide Genetic Test predict who will tolerate GLP-1s?

Not as a yes/no prediction. The test reports variants associated with differential GLP-1 and GIP response — including GIPR rs1800437 — that inform titration and mechanism choice. It is a clinical input, not a guarantee, and it does not override the FDA-labeled contraindications. The test is $298 standalone or $99 as an add-on after your first month on a PlexusDx protocol.

What if I cannot stop vomiting on a GLP-1?

Stop trying to push through it — contact your provider promptly. Focus on small sips of water, oral rehydration solutions, or clear broth. If you cannot keep any fluids down for 24 hours, see signs of severe dehydration, or vomit blood, go to an emergency department. PlexusDx patients can message the clinical team between visits for guidance.

Are PlexusDx protocols FDA-approved?

The compounded semaglutide and tirzepatide formulations PlexusDx prescribes are not FDA-approved finished drugs — only branded products like Wegovy, Ozempic, Zepbound, and Mounjaro are. The active ingredients are the same, and PlexusDx works with licensed U.S. compounding pharmacies and licensed clinicians under standard compounding regulations. The labeled GLP-1 class side effects, contraindications, and boxed warning all apply.

Related reading on PlexusDx

Related reading on PlexusDx: Semaglutide Side Effects, Tirzepatide Side Effects, GLP-1 Cost, Cheapest GLP-1.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Information about FDA-labeled side effects, contraindications, and the thyroid C-cell boxed warning is summarized from public FDA prescribing information current as of April 2026; actual product labeling and individual risk may vary. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision — including starting, stopping, or changing dose — with a licensed clinician.